Hair thinning in the menopause transition
When hair loses fullness - often a hormonal signal.
Many women notice thinner hair, more breakage, or increased shedding in the brush. Hair changes can hit self-esteem hard. About 40% of women experience visible hair density or texture change during hormonal transition. This is not “just cosmetic” - it often reflects internal shifts. In the menopause transition, estrogen–androgen balance moves. Understanding that internal medicine context helps you support hair health from the inside out.
of women notice visible changes in hair fullness during midlife transition. [3]
The internal medicine lens
“Hair shedding in midlife is often a metabolic signal - not vanity. When we fix the drivers, hair often follows.”
Hair follicles are exquisitely sensitive to hormones. Estrogen supports the growth phase (anagen) and hair shaft quality. As estrogen falls in the menopause transition, growth phases can shorten.
Relative androgen dominance can increase dihydrotestosterone (DHT) effects in susceptible individuals, shrinking follicles and thinning the mid-scalp pattern.
Hair is also a “luxury tissue”: in nutrient stress or metabolic strain, the body prioritizes vital organs first.
Thyroid function and iron stores (ferritin) are non-negotiable checks - both are essential for follicle cell division. Stress and poor sleep raise cortisol and can worsen shedding.
Symptoms often cluster: hot flashes and mood changes can share hormonal roots with hair changes.
Follicles can recover: when nutrition, thyroid, iron, and hormones align, many women see meaningful improvement within 6–12 months.
Why Dr. Lorenz?
I take hair shedding seriously and evaluate thyroid, iron status, inflammation, and androgen patterns - not only “female hormones.”
My two-visit pathway includes detailed history and labs (ferritin, zinc, biotin when indicated, thyroid panel, hormones) and a practical plan (see About).
What could be going on?
Differential diagnoses
Hair thinning is often a clue to a deeper imbalance. Precise evaluation beats guessing with supplements.
Iron deficiency (ferritin)
Low iron stores are a leading cause of diffuse shedding in women.
Thyroid dysfunction
Both hypo- and hyperthyroidism can change hair quality. (See thyroid.)
Telogen effluvium
Shedding often begins months after illness, surgery, or major stress - timing matters.
Autoimmune hair loss
Conditions like alopecia areata or lupus-related patterns need targeted diagnosis.
Evaluation should identify the mechanism - not only the symptom.
What actually helps?
Evidence-based options
This section reflects current guideline recommendations [1] .
Hormone therapy (HT) [2]
Estrogen can support growth phase duration and reduce androgenic drive in selected patients. [4]
Targeted nutrients
Iron, zinc, vitamin D, and protein adequacy - guided by labs.
Stress recovery
Lowering cortisol load supports follicle biology alongside hormones.
We review evidence practically - without overpromising.
When should you see a doctor?
Many perimenopause symptoms are benign, but the warning signs below should be evaluated promptly:
Sudden patchy hair loss suggesting alopecia areata
Scalp scarring, burning, or severe inflammation
Loss of eyebrows/eyelashes with systemic symptoms
What patients say about the clarification pathway
€490 for an online visit? I was skeptical. After 60 minutes in the first appointment, it was clear: I do not get that depth with a standard office visit.
M.
Patient, Cologne
Anonymized case example
Next step
Thinner hair - and no one finds a clear cause?
I evaluate hormones, thyroid, iron, and stress physiology so you can act with a plan - not fear.
The Perimenopause Clarification is a structured two-visit program with intake, targeted diagnostics, and a written care plan. Package price €490. Lab fees are billed separately by the laboratory (typically €80–280).
Medical sources
This page is not a substitute for individualized medical advice. Key clinical statements link to the sources below.
- [1] NICE Guideline NG23: Menopause - diagnosis and management (NICE, 2024, Leitlinie) Open source
- [2] The 2022 hormone therapy position statement of The North American Menopause Society (Menopause, 2022, Positionspapier) Open source
- [3] Menopause, skin and common dermatoses. Part 1: hair disorders (Clinical and Experimental Dermatology, 2022, Narrative Review) Open source
- [4] The Hormonal Background of Hair Loss in Non-Scarring Alopecias (Biomedicines, 2024, Narrative Review) Open source
Last clinically reviewed 2026-04-15. Reviewed by Dr. med. Christin Lorenz (Ärztin mit internistischem Schwerpunkt).
From the journal
In-depth articles on this topic (German)